SynAct Pharma develops drugs for acute deterioration in inflammatory diseases.
SynAct Pharma has raised $1.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2025.
SynAct Pharma's investors include Heights Capital Management, EISMEA.
SynAct Pharma is headquartered in Lund, Sweden.
SynAct Pharma develops drugs for acute deterioration in inflammatory diseases.
SynAct Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SynAct Pharma — Funding & Investors." VCBacked, July 15, 2025, https://www.vcbacked.co/company/synact-pharma. Accessed September 30, 2026.
VCBacked. (2025). SynAct Pharma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/synact-pharma
{{cite web |title=SynAct Pharma — Funding & Investors |url=https://www.vcbacked.co/company/synact-pharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated